Agios Pharmaceuticals Highlights 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction

Company outlines upcoming clinical and regulatory milestones, discusses early commercial progress for thalassemia treatment.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Agios Pharmaceuticals executives provided an update on the company's pipeline and commercial progress during a healthcare conference. They highlighted several key milestones expected in 2026, including regulatory meetings for the sickle cell disease indication of PYRUKYND (mitapivat) and Phase 2 readouts for the more potent PK activator tebapivat in myelodysplastic syndrome and sickle cell disease. Executives also discussed early launch indicators for PYRUKYND in thalassemia, noting a favorable safety profile and positive physician and patient response.

Why it matters

Agios is positioning PYRUKYND as the foundation of its pyruvate kinase activation franchise, with the thalassemia launch seen as an important early commercial milestone. The company's pipeline progress, particularly in sickle cell disease and myelodysplastic syndrome, could unlock additional growth opportunities if the data continues to show promise.

The details

Agios highlighted several upcoming catalysts for 2026, including a planned FDA meeting in Q1 regarding a potential supplemental NDA (sNDA) for PYRUKYND in sickle cell disease. The company said it will disclose its regulatory strategy after receiving the meeting minutes. Additionally, Agios has two fully enrolled Phase 2 studies for its more potent PK activator tebapivat, with readouts expected in the first half (myelodysplastic syndrome) and second half (sickle cell disease) of 2026. Discussing the RISE UP Phase 3 trial in sickle cell disease, Agios noted the study met the hemoglobin endpoint but did not achieve statistical significance for the vaso-occlusive crisis (VOC) reduction endpoint. However, the company highlighted a 'very strong anti-hemolytic finding,' with 41% of patients achieving a hemoglobin improvement of at least 1 gram. It also cited statistically significant improvements in other markers of hemolysis.

  • Agios plans to have a pre-sNDA meeting with the FDA in the first quarter of 2026 regarding PYRUKYND in sickle cell disease.
  • A Phase 2b readout for tebapivat in lower-risk myelodysplastic syndrome is expected in the first half of 2026.
  • Top-line results for tebapivat in sickle cell disease are expected in the second half of 2026.

The players

Agios Pharmaceuticals

A biopharmaceutical company focused on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases.

Brian Goff

Chief Executive Officer of Agios Pharmaceuticals.

Tsveta Milanova

Chief Commercial Officer of Agios Pharmaceuticals.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.